Perioperative Outcomes of Anatomic Lung Resections in Patients Who Recovered From Coronavirus Disease 2019: a Two-Year Retrospective Case Series
This study will determine the outcomes of anatomic lung resections in patients who recovered from coronavirus disease 2019 (COVID-19) disease by describing the morbidity and mortality as well as the length of postoperative hospital stay.
|Condition or Disease||Intervention/Treatment||Phase|
This study will be conducted at the Lung Center of the Philippines. The study design is a retrospective case series implemented via chart review. Online and written patient records will be reviewed to determine the baseline patient characteristics and the preoperative outcomes. Patients who recovered from COVID-19 will be selected from those who underwent anatomic lung resection from June 1, 2020 to May 31, 2022. This study will be done in accordance with the Helsinky Declaration and Good Clinical Practice Guidelines, and will be subject for approval of the institutional Ethics and Technical Review Boards. Descriptive statistics will be used to describe patient characteristics and perioperative outcomes.
Arms and Interventions
|patients who recovered from COVID-19
patients with previous COVID-19 infection who underwent anatomic lung resection (segmentectomy, lobectomy, bilobectomy or pneumonectomy)
Procedure: anatomic lung resection
includes minimally invasive or open lung segmentectomy, lobectomy, bilobectomy and pneumonectomy
Primary Outcome Measures
- Mortality [perioperative period (up to 30 days after anatomic lung resection)]
cause of death should be a perioperative complication
- Major complication [perioperative period (up to 30 days after anatomic lung resection)]
includes acute kidney injury, acute myocardial infarction, acute respiratory distress syndrome (ARDS), acute respiratory failure, atelectasis requiring intervention, bronchopleural fistula, empyema thoracis, hemothorax, pneumonia, stroke and venous thromboembolism
- Minor complications [perioperative period (within 30 days after anatomic lung resection)]
includes atrial fibrillation, pneumothorax and prolonged air leak
- length of postoperative hospital stay [perioperative period (up to 30 days after anatomic lung resection)]
time duration from surgery to discharge order
underwent anatomic lung resection
previous COVID-19 infection documented by nasopharyngeal swab RT-PCR or GeneXpert
with negative nasopharyngeal swab RT-PCR or GeneXpert prior to lung resection
- with incomplete patient records
Contacts and Locations
LocationsNo locations specified.
Sponsors and Collaborators
- Lung Center of the Philippines
- Principal Investigator: Alexander H Tuliao, MD, Lung Center of the Philippines
Study Documents (Full-Text)None provided.
- COVIDSurg Collaborative; GlobalSurg Collaborative. Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study. Anaesthesia. 2021 Jun;76(6):748-758. doi: 10.1111/anae.15458. Epub 2021 Mar 9.
- Diaz A, Bujnowski D, McMullen P, Lysandrou M, Ananthanarayanan V, Husain AN, Freeman R, Vigneswaran WT, Ferguson MK, Donington JS, Madariaga MLL, Abdelsattar ZM. Pulmonary Parenchymal Changes in COVID-19 Survivors. Ann Thorac Surg. 2022 Jul;114(1):301-310. doi: 10.1016/j.athoracsur.2021.06.076. Epub 2021 Jul 31.
- Nefedov A, Mortada M, Novitskaya T, Patsyuk A, Kozak A, Yablonskii P. Lobectomy with pathological examination in lung cancer patients who recovered from COVID-19. Gen Thorac Cardiovasc Surg. 2021 Aug;69(8):1258-1260. doi: 10.1007/s11748-021-01632-2. Epub 2021 Apr 9.
- Sakai T, Azuma Y, Aoki K, Wakayama M, Miyoshi S, Kishi K, Tateda K, Homma S, Iyoda A. Elective lung resection after treatment for COVID-19 pneumonia. Gen Thorac Cardiovasc Surg. 2021 Jul;69(7):1159-1162. doi: 10.1007/s11748-021-01630-4. Epub 2021 Apr 3.
- Testori A, Perroni G, Voulaz E, Crepaldi A, Alloisio M. Pulmonary Lobectomy After COVID-19. Ann Thorac Surg. 2021 Mar;111(3):e181-e182. doi: 10.1016/j.athoracsur.2020.08.004. Epub 2020 Sep 25.